Dimebon for Alzheimer's disease
References
Additional references
Alzheimer’s Association. 2010 Alzheimer's disease facts and figures. Alzheimers & Dementia 2010;6(2):158‐94.
Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochemical Society Symposia 2001;67:73‐80.
Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Annals of the New York Academy of Sciences 2001;939:425‐35.
Bachurin S, Shevtsova E, Kireeva E, Oxenkrug G, Sablin S. Mitochondria as a target for neurotoxins and neuroprotective agents. Annals of the New York Academy of Sciences 2003;993:334‐44.
Bassil N, Grossberg G. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009;23(4):293‐307.
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue Art. No.: CD005593.
Brookmeyer R, Johnson E, Ziegler‐Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers & Dementia 2007;3:186‐91.
Doody R, Gavrilova S, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild‐to‐moderate Alzheimer’s disease: a randomised, double‐blind, placebo‐controlled study. Lancet 2008;372:207‐15.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353‐6.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org. The Cochrane Collaboration.
Jones R. Dimebon disappointment. Alzheimers Research & Therapy 2010;2:25.
Kanamarua Y, Kikukawaa A, Miyamotoa Y, Hirafujib M. Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin‐A during cognitive tasks. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 2008;32(1):107‐15.
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurology 2010;9(7):702‐16.
McGreer PL, McGreer, E.G. NSAIDs and Alzheimer's disease: epidemiological, animal, model and clinical studies. Neurobiology of Aging 2007;28(5):639‐47.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939‐44.
McShane R, Sastre AA, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue Art. No.: CD003154.
Rafii M, Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Medicine 2009;7:7.
Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, et al. Preclinical study of dimebon on B‐amyloid‐mediated neuropathy in Alzheimer's disease. Molecular Neurodegeneration 2011;6(1):7.
Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Molecular Neurodegeneration 2008;3:15.
| Source | Search Strategy |
| Medline (Ovid SP) | 1. latriperdine.mp. 2. dimebon.mp. 3. dimebolin.mp. 4. 2,3,4,5‐tetrahydro‐2,8‐dimethyl‐5‐(2‐(6‐methyl‐3‐pyridyl)ethyl)‐1H‐pyrido(4,3‐b)indole.mp. 5. (1 OR 2 OR 3 OR 4) 6. (Alzheimer* OR AD).mp. 7. Alzheimer Disease/ 8. Dement*.mp. 9. (6 OR 7 OR 8) 10. (5 AND 9) 11. randomized controlled trial.pt. 12. controlled clinical trial.pt. 13. randomized.ab. 14. "randomized controlled trial".tw. 15. placebo.ab. 16. drug therapy.fs. 17. randomly.ab. 18. trial.ab. 19. groups.ab. 20. (11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19) 21. humans.sh. 22. (20 AND 21) 23. (10 AND 22) |
Figures and Tables -
Table 1. Search strategy for MEDLINE
